HCPLive

HCPLive HCPLive.com is your one-stop shop for healthcare news, medical conference coverage, and more. Clinical News for Connected Physicians

When it comes to selecting a biologic for severe asthma, biomarkers are only part of the equation. Payel Gupta, MD, alle...
06/11/2026

When it comes to selecting a biologic for severe asthma, biomarkers are only part of the equation. Payel Gupta, MD, allergist and immunologist at Ease Allergy Clinic and Mount Sinai, breaks down how IgE, FeNO, and blood eosinophil counts inform first-line biologic choice, as well as where the the field still falls short of true precision medicine.
Key clinical takeaways from her conversation with HCPLive:
• About 10% of patients don't respond to the first biologic selected
• If a patient isn't improving within 1–2 months, Gupta typically looks to switch to an agent with a different mechanism of action
• Type 2 comorbidities (atopic dermatitis, EoE, CRSwNP, CSU) can tip the scale toward a biologic approved across multiple indications—a potential "2-for-1" benefit
Read the full Q&A here: https://hubs.li/Q04k_rdD0

That's a wrap on our live coverage of day 2 of ! We'll be back tomorrow to deliver more key clinician insights and majo...
06/09/2026

That's a wrap on our live coverage of day 2 of ! We'll be back tomorrow to deliver more key clinician insights and major trial news, so keep an eye on https://hubs.li/Q04kpH9_0 for the latest!

New at : Presented in tandem with the TRANSCEND-T2D-1 trial, TRIUMPH-1 has shown retatrutide's groundbreaking weight-lo...
06/09/2026

New at : Presented in tandem with the TRANSCEND-T2D-1 trial, TRIUMPH-1 has shown retatrutide's groundbreaking weight-loss efficacy in patients with obesity or overweight. Read more about the world's first triple agonist here: https://hubs.li/Q04kpxyx0

Last call for RAD 2026!If you've been on the fence, now's the time. RAD 2026 is just around the corner — join us June 17...
06/09/2026

Last call for RAD 2026!

If you've been on the fence, now's the time. RAD 2026 is just around the corner — join us June 17–19 at the Four Seasons Hotel Nashville for three days of cutting-edge atopic dermatitis education, expert discussions, and meaningful connections.

Evidence drives the conversation. Strategies get built. And this year, it all happens in Music City. 🎶

Register today and come ready to level up your AD practice: https://hubs.li/Q04kktYr0

06/07/2026

New at : In the phase 2 ZUPREME-1 trial, human amylin analog petrelintide delivered significant weight loss while maintaining tolerability comparable to GLP-1 therapies in patients with overweight and obesity with complications.

Watch our full interview with Timothy Garvey, MD, here: https://hubs.li/Q04kqmFR0

06/07/2026

New at : Newly published results from the phase 3 SYNCHRONIZE-1 trial of survodutide have shown substantial weight reductions driven almost exclusively by fat mass, with potential benefits for metabolic health beyond.

Watch our full interview with the presenter, Carel le Roux, PhD, of University College Dublin, here: https://hubs.li/Q04knVZX0

06/06/2026

In the latest episode of Diabetes Dialogue, recorded live at , cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by guest Eugene Wright Jr, MD, to discuss the ADA's statement on technology integration in diabetes care.

Watch now: https://hubs.li/Q04kpvQ_0

New at : Retatrutide, the first GLP-1/GIP/glucagon triple agonist to reach phase 3 testing, has demonstrated substantia...
06/06/2026

New at : Retatrutide, the first GLP-1/GIP/glucagon triple agonist to reach phase 3 testing, has demonstrated substantial results in A1c reduction and weight loss among patients with type 2 diabetes. Read more about the groundbreaking TRANSCEND-T2D-1 trial here: https://hubs.li/Q04kp3__0

HCPLive is officially on-site at in New Orleans! For the rest of the weekend, we'll be covering major trial results an...
06/05/2026

HCPLive is officially on-site at in New Orleans! For the rest of the weekend, we'll be covering major trial results and providing key clinician insights on the latest news in diabetes care. Keep an eye on https://hubs.li/Q04kgq0f0 for more!

Optimizing IL-23–targeted therapy in IBD: when to switch, how to sequence, and what the long-term efficacy and safety da...
06/03/2026

Optimizing IL-23–targeted therapy in IBD: when to switch, how to sequence, and what the long-term efficacy and safety data shows.

Join a regional roundtable discussion in Dallas, moderated by Bincy Abraham, MD, MS — a peer-to-peer forum on applying new science in community practice.

Thursday, June 4 · 6:30–8:30 PM CDT · Perry's Steakhouse & Grille, Dallas.
Seats are limited — register now: https://hubs.li/Q04jYnzv0

Address

2 Clarke Drive
Cranbury, NJ
08512

Opening Hours

Monday 8:30am - 5:30pm
Tuesday 8:30am - 5:30pm
Wednesday 8:30am - 5:30pm
Thursday 8:30am - 5:30pm
Friday 8:30am - 5:30pm

Website

Alerts

Be the first to know and let us send you an email when HCPLive posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to HCPLive:

Shortcuts

Share

Category